Labcorp Holdings Inc. (LH)
After hours:
| Previous Close | 214.90 |
| Open | 215.48 |
| Bid | 211.07 x 1000 |
| Ask | 230.00 x 1000 |
| Day's Range | 215.43 - 217.47 |
| 52 Week Range | 191.97 - 238.47 |
| Volume | |
| Avg. Volume | 535,631 |
| Market Cap | 18.169B |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | 40.15 |
| EPS (TTM) | 5.39 |
| Earnings Date | Oct 24, 2024 |
| Forward Dividend & Yield | 2.88 (1.33%) |
| Ex-Dividend Date | Nov 26, 2024 |
| 1y Target Est | 255.00 |
PR NewswireLabcorp Expands Sexually Transmitted Infection (STI) Test Offerings with Rapid Syphilis Test
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it has expanded its portfolio of sexually transmitted infection (STI) testing options to include the First to Know® Syphilis Test, the first over-the-counter blood test granted market authorization by the U.S. Food & Drug Administration (FDA) that can be performed by both physicians and patients.
PR NewswireLabcorp Declares Quarterly Dividend
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 13, 2024, to stockholders of record as of the close of business on November 26, 2024.
ZacksLabcorp Stock Gains From Biopharma Business Amid FX Woe
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
